265 related articles for article (PubMed ID: 11448727)
21. Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo.
Agrawal S; Zhao Q
Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):135-9. PubMed ID: 9593053
[No Abstract] [Full Text] [Related]
22. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
23. Current status of delivery systems to improve target efficacy of oligonucleotides.
Shoji Y; Nakashima H
Curr Pharm Des; 2004; 10(7):785-96. PubMed ID: 15032703
[TBL] [Abstract][Full Text] [Related]
24. Does antisense make sense in dermatology?
van Erp PE; Wingens M
Acta Derm Venereol; 2001; 81(6):385-91. PubMed ID: 11859937
[TBL] [Abstract][Full Text] [Related]
25. Antisense strategies.
Crooke ST
Curr Mol Med; 2004 Aug; 4(5):465-87. PubMed ID: 15267220
[TBL] [Abstract][Full Text] [Related]
26. Antisense strategies for oncogene inactivation.
Stein CA; Benimetskaya L; Mani S
Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
[TBL] [Abstract][Full Text] [Related]
27. Antisense oligonucleotide-based therapeutics for cancer.
Dean NM; Bennett CF
Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
[TBL] [Abstract][Full Text] [Related]
28. Shutting down a gene. Antisense drug wins approval.
Stix G
Sci Am; 1998 Nov; 279(5):46, 50. PubMed ID: 9841380
[No Abstract] [Full Text] [Related]
29. Significant inhibitory effects of Hybridon's antisense compound on various HIV-1 replication steps in in vitro tests.
AIDS Patient Care STDS; 1996 Dec; 10(6):375-6. PubMed ID: 11361558
[No Abstract] [Full Text] [Related]
30. [Oligonucleotide therapeutics - an emerging novel class of compounds].
Wacheck V
Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803
[TBL] [Abstract][Full Text] [Related]
31. Antisense has growing pains.
Gura T
Science; 1995 Oct; 270(5236):575-7. PubMed ID: 7570012
[No Abstract] [Full Text] [Related]
32. Sense antisense nonantisense. Can these novel antivirals knock HIV senseless?
Chang HE; Mascolini M
J Int Assoc Physicians AIDS Care; 1995 Feb; 1(1):11-8. PubMed ID: 11362229
[TBL] [Abstract][Full Text] [Related]
33. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
[TBL] [Abstract][Full Text] [Related]
34. Antisense therapeutics: from theory to clinical practice.
Pirollo KF; Rait A; Sleer LS; Chang EH
Pharmacol Ther; 2003 Jul; 99(1):55-77. PubMed ID: 12804699
[TBL] [Abstract][Full Text] [Related]
35. Antisense approaches in drug discovery and development.
Rayburn E; Wang W; Zhang R; Wang H
Prog Drug Res; 2005; 63():227-74. PubMed ID: 16265883
[No Abstract] [Full Text] [Related]
36. Antisense technology: an emerging platform for cardiovascular disease therapeutics.
Lee RG; Crosby J; Baker BF; Graham MJ; Crooke RM
J Cardiovasc Transl Res; 2013 Dec; 6(6):969-80. PubMed ID: 23856914
[TBL] [Abstract][Full Text] [Related]
37. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics.
Arora V; Devi GR; Iversen PL
Curr Pharm Biotechnol; 2004 Oct; 5(5):431-9. PubMed ID: 15544491
[TBL] [Abstract][Full Text] [Related]
38. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
39. Antisense anticancer oligonucleotide therapeutics.
Wang H; Prasad G; Buolamwini JK; Zhang R
Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878
[TBL] [Abstract][Full Text] [Related]
40. Still looking for the real GEM.
GMHC Treat Issues; 1996 Apr; 10(4):9. PubMed ID: 11363711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
